Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-HT547 and [177Lu]Lu-HT547 in Solid Tumors
NCT07639970Phase 1Not yet recruiting
- Sponsor
- Huabang Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Jun 2027
01
Overview
Phase 1, open-label, single-arm trial of HT547 in breast cancer, head and neck cancer (HNC), pancreatic cancer (PC) and 1 more, sponsored by Huabang Pharmaceutical. Primary endpoint: Diagnostic efficacy. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HT547
03
Conditions
breast cancerhead and neck cancer (HNC)pancreatic cancer (PC)glioma
Beyond the preview
Go deeper on NCT07639970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639970.